Introduction
============

The combination of ataxia and peripheral neuropathy (PN) may be associated with a variety of conditions such as paraneoplastic syndromes, celiac disease (CD), Sjogren's syndrome, chronic inflammatory demyelinating polyneuropathy, and Miller-Fisher syndrome, ([@b13-jmdh-1-93]; [@b16-jmdh-1-93]; [@b15-jmdh-1-93]). CD is a multigenetic T-cell mediated autoimmune disease where intolerance develops to the dietary protein 'gluten'. CD typically presents with gastrointestinal manifestations but in some cases ataxia can be the presenting sign. Other extraintestinal manifestations include iron-deficiency anemia, osteoporosis, cryptogenic hypertransaminasemia, recurrent abortion, autoimmune diseases which are now recognized to be more common in the absence of gastrointestinal symptoms in patients with gluten-sensitive enteropathy. It has been estimated from prevalence studies that for every patient with CD who presents with gartrointestinal symptoms, there are eight patients with silent disease. Since diabetes is a major cause of PN ([@b8-jmdh-1-93]; [@b23-jmdh-1-93]) there is complacency about seeking alternative causes of neurological syndromes in such patients. Autoimmune pathogenetic mechanisms have been implicated in neuropathy in diabetes ([@b9-jmdh-1-93]). It is unclear whether the antibodies are pathogenic or innocent bystanders ([@b24-jmdh-1-93]), but there is little doubt that there is a greater frequency of inflammatory demyelinating neuropathies in people with diabetes than in the general population ([@b22-jmdh-1-93]). The association of cerebellar ataxia and PN in diabetes has been reported in a patient with circulating GAD antibodies ([@b14-jmdh-1-93]). The prevalence of CD in children with juvenile diabetes is at least 4.6% ([@b1-jmdh-1-93]) and is known it is known to be a hall mark of type-1 diabetes. However, CD may occur in type 2 diabetes or in latent autoimmune diabetes of adult ([@b21-jmdh-1-93]). Thus, it is not surprising to find CD in older males with diabetes. We present a case of cerebellar ataxia associated with CD without gastrointestinal involvement in a patient with well-controlled diabetes in whom treatment of the autoimmunity reversed the PN, but not the ataxia.

Case report
===========

A 70-year-old Caucasian male with a 3 ½ year history of type 2 diabetes, presented with complaints of unsteadiness. He had numbness in his feet and erectile dysfunction. He took irbersartan for hypertension and had a strong family history of type 2 diabetes but no autoimmune diseases.

His musculoskeletal system showed bilateral mild wasting of the quadriceps and total loss of vibration sensation in the feet. Pinprick sensation was reduced in both his lower limbs to the level of the ankles but only a mild reduction in the upper limbs. Tendon reflexes were intact. Romberg's sign was negative. Tandem stand test was strongly positive as was the one-legged stand test. Two months later he exhibited gait ataxia, hypermetria, and intention tremor.

Extensive testing for possible causes was done. Paraneoplastic antibodies, urinary heavy metal excretion, serum electrophoresis, ANA, RPR, and HIV tests were negative. A MRI of the spine and brain did not reveal any pathology, PET scan of the lungs for occult malignancy was negative and CSF was normal. Vitamin E and vitamin B~12~, TSH, ceruloplasmin, and lactic acid levels were all normal. His HbA1c was 6.4%. Since this clinical presentation was distinctly unusual for diabetes, we investigated further for autoimmune neuropathy and incubated his serum with N1E-115 neuroblastoma cells which showed apoptotic cell death confirming the autoimmune etiology ([@b20-jmdh-1-93]).

Electromyography showed supranormal conduction velocities over the peroneal, tibial, medial, ulnar, and sural nerves but low amplitudes indicating a mild axonal form of neuropathy. Quantitative sensory testing (QST) revealed a mild large-fiber neuropathy with impaired vibration perception and relatively intact warm and cold thermal perception in the feet. All these findings were compatible with a metabolic disease such as diabetes. Hence, diet, exercise and oral hypoglycemic therapy were initiated to control the diabetes and in light of the strongly positive effects of his serum on immunotoxicity assay, we initiated intravenous immunoglobulin (IVIg) therapy along with oral antioxidant therapy (Vitamin C, 500 mg/day; Vitamin E, 400 IU/day; alphalipoic acid,1200 mg/day; and dihomogammalinolenic acid, 3900 mg/day). The magnetic resonance scan of his brain revealed evidence of moderate cerebellar atrophy.

Six months later, his neuropathy had improved except for mild impairment of vibration perception. However, cerebellar signs were still present. By this time he had completed two infusions of intravenous immunoglobulin (IVIg) (1 g/kg/day × 2) but unfortunately he developed a centripetal rash after the 2nd infusion, and no further IVIg was given. The patient's serum remained toxic to neuronal cells in culture despite the administration of IVIg. [Table 1](#t1-jmdh-1-93){ref-type="table"} shows the improvement in QST and autonomic nerve function tests at presentation and 17 months into treatment.

These progressively worsening cerebellar signs were thought to be due to an autoimmune process, as the serum was very toxic to neuroblastoma cells. Antigliadin IgG, antigliadin IgA and antireticulin antibodies were found to be positive among many other antibody panels that were investigated. Other antibodies including, paraneoplastic antibodies, anti-GAD antibodies, antithymoglobin, antimicrosomal, anti-R1, anti-Ma/Ta, antiendomysial antibodies, anti-Yo-antibody, anti-Hu antibody, antineural antibodies (ANNA-1 and ANNA-2) and Lyme titers were negative (these tests were performed by LabCorp, Burlington, NC). Small bowel studies including esophagogastroduodenoscopy and biopsies of small bowel failed to show any evidence of CD. Though there was no biopsy evidence of CD, he was advised to embark on a gluten-free diet based on case reports that suggested that ataxia could be the sole manifestation of CD in the absence of gastrointestinal pathology and based on antibody positivity. There was also the possibility that the intestinal biopsy had missed the affected site.

After 2-months on a gluten-free diet, his peripheral neuropathy showed further improvement but he still had all the signs of cerebellar dysfunction supporting the notion of different mechanisms for the cerebellar ataxia and the peripheral neuropathy. After 20 months on the diet, all the celiac antibody titers became normal and the PN showed progressive improvement but the cerebellar function did not. [Figure 1](#f1-jmdh-1-93){ref-type="fig"} shows the clinical improvement over time.

Discussion
==========

This patient has progressive cerebellar ataxia, improving peripheral neuropathy and decreasing titers of celiac antibodies. Hence, it is compelling to consider CD as the cause of his condition. Cerebellar ataxia could be the only manifestation of an otherwise occult CD in this patient. Sensory axonal neuropathies and small fiber polyneuropathies are the most frequently reported types of peripheral neuropathy in CD ([@b6-jmdh-1-93]). There are reports to suggest that ataxia could be the sole manifestation of CD especially in people with a genetic susceptibility ([@b11-jmdh-1-93]; [@b4-jmdh-1-93]). There is growing evidence of the association of CD with many neurological disorders ([@b10-jmdh-1-93]). These conditions include cerebellar ataxia, PN, epilepsy, dementia, and depression. Among these, cerebellar ataxia, PN and memory impairment are the most commonly seen associations ([@b11-jmdh-1-93]; [@b18-jmdh-1-93]; [@b19-jmdh-1-93]). There is also some suggestion that migraine, encephalopathy, chorea, brain-stem dysfunction, myelopathy, mononeuritis multiplex and Guillian-Barre like syndrome could be the presenting extra-intestinal manifestations of CD with or without intestinal pathology ([@b3-jmdh-1-93]).

Although ataxia is believed to be due to immunological damage to the cerebellum, posterior column, and peripheral nerves ([@b11-jmdh-1-93]), it is unclear whether there is a common pathogenic mechanism that affects both the nervous system and the gastrointestinal tract. Ataxia in CD can be due to malabsorption and associated vitamin deficiency ([@b12-jmdh-1-93]). There is a report where parenteral vitamin E administration improved the clinical and neurophysiological signs of CD in a vitamin E-depleted patient with this disease ([@b2-jmdh-1-93]). However, our patient had normal Vitamin E levels and had received vitamin E.

A gluten-free diet is the main modality of treatment for CD. Other therapies include IVIg and infliximab ([@b5-jmdh-1-93]). Although there are reports that gluten-free diet has improved survival and quality of life, facilitated the normal growth and development in infants, prevented osteopenia and decreased the risk of T-cell lymphoma in adults, its effect on the nervous system has been variable ([@b17-jmdh-1-93]). There are reports where ataxia and PN persisted or even progressed with gluten free diet ([@b17-jmdh-1-93]; [@b5-jmdh-1-93]).

Our patient demonstrates a dichotomy between the responses of PN, autonomic neuropathy and cerebellar ataxia to a gluten-free diet. Nonetheless the frequency of coexistence of CD in diabetes and the responsiveness of PN to therapy would encourage a search for the presence of CD in patients with diabetes and neuropathy. Strikingly, the PN improved with measures to reduce autoimmunity supporting the notion that there may be an autoimmune mechanism for damage to peripheral nerves that can be resolved. Unfortunately, this does not appear to be the case for the cerebellar component for reasons that are not apparent at this point in time. The occurrence of cerebellar ataxia emphasizes the need to consider CD and requires further investigation into possible pathogenetic mechanisms which appear to be distinct from that of the PN.
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![This figure represents the progressive changes in central and peripheral nervous system scores. The central nervous system (CNS) signs score is the sum of the number of positive cerebellar signs. The total peripheral neuropathy impairment scores and sensory scores were obtained from our clinical evaluation scoring system ([@b27-jmdh-1-93]) modified from the Rochester Diabetic Neuropathy Study ([@b7-jmdh-1-93]). In this system a score of 1 or 0 is given for the presence or absence of neuropathy symptom respectively. Motor, sensory and autonomic nervous systems are evaluated and given scores on a scale of 0 to 4, 0 being no impairment and 4 being severe impairment. Antioxidant treatment instituted at point A, IV Ig infusion instituted at point B and Point C is when gluten free diet was started.](jmdh-1-93f1){#f1-jmdh-1-93}

###### 

Quantitative measures of peripheral sensory threshold indices and autonomic function done at the time of presentation and after 17 months of treatment. Measures of peripheral neuropathy are vibration and pressure sensations, warm and cold perceptions and painful perception ([@b26-jmdh-1-93]). The E/I (exipiratory/inspiratory ratio), 30:15 stand test and valsalva are measures of autonomic nerve function ([@b25-jmdh-1-93])

  Neuropathy t tests(units)   At presentation   After 17 months   Normal values for \>90% specificity
  --------------------------- ----------------- ----------------- -------------------------------------
  Vibration (volts)           9.11              3.63              0--6.1
  Pressure (log g)            4.13              3.58              0--3.95
  Cold perception (°C)        8.6               9.2               0--10.5
  Warm Perception (°C)        10.3              9.3               0--12.4
  Cold pain(°C)               24                11.1              0--23.3
  Warm pain (°C)              15.5              10.4              0--17.7
  E/I                         1.11              1.06              \>1.08
  Valsalva                    1.57              1.21              \>1.15
  30:15 ratio                 1.13              1.05              \>1.08
